Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00365170
Status:
COMPLETED
Last Update Posted:
2016-12-21
First Post:
2006-08-10
Brief Title:
Efficacy and Safety of Insulin Aspart vs Human Insulin During Pregnancy by Women With Type 1 Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
A Randomised Parallel-group Open-label Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart NovoRapid Versus Human Insulin Actrapid Used in a Multiple Injection Regimen in the Treatment of Pregnant Women With Type 1 Diabetes Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial was conducted in Europe Middle East North America and South America
The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart NovoRapid versus human insulin Actrapid in pregnancy
The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart NovoRapid versus human insulin Actrapid in pregnancy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None